Orchid Pharma has scheduled its 33rd Annual General Meeting for September 29, 2026. The meeting will address the ratification of a ₹400 crore related-party transaction limit with Otsuka Chemicals (India) Private Limited and the appointment of Mr. Arjun Dhanuka as Whole-Time Director.

The Board convened on September 3, 2026, to approve these matters in compliance with SEBI Listing Regulations. The AGM will be held via Video Conferencing/Other Audio Visual Means (VC/OAVM).

Related Party Transaction Approval

Shareholders are asked to approve material related-party transactions with M/s. Otsuka Chemicals (India) Private Limited for FY27. The proposed ceiling is ₹400 crore for the purchase of goods, specifically the key raw material GCLE (Advanced Cephalosporin Drug Intermediate).

Otsuka is the sole approved source for GCLE. The relationship arises because Mr. Manish Dhanuka (Managing Director) and Mr. Mridul Dhanuka (Whole-Time Director) are directors/members of Otsuka. Transactions in Q1FY26 stood at ₹6,317.48 lakh, while total FY25-26 purchases were ₹24,498 lakh.

Leadership Appointments

Mr. Arjun Dhanuka will serve as Whole-Time Director from September 3, 2026, to September 2, 2031. His monthly salary is set at ₹8 lakh with a 10% annual increment. He previously served as a Non-Executive Non-Independent Director.

Additionally, Mr. Mridul Dhanuka retires by rotation and offers himself for reappointment as Whole-Time Director.

Cost Auditor & Logistics

M/s. J Karthikeyan & Associates was appointed as Cost Auditor for FY27. Shareholders must ratify their remuneration of ₹3.5 lakh plus taxes.

The remote e-voting window opens on September 26, 2026, at 9:00 am and closes on September 28, 2026, at 5:00 pm. The record date for voting eligibility is September 22, 2026.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE191A01027/7ff86789-32d3-4f65-ac2c-9081b18f470c.pdf

Orchid Pharma confirmed that its 7-ACA backward integration project is set to begin operations by March 2027. The company stated that commissioning and the first commercial batch are targeted for this timeline.

This update reinforces the strategic roadmap previously outlined, where the project aims to reach 80-100% utilization by the end of its first year. Management has indicated that 80% of the output is intended for in-house use, with the remaining 20% allocated for third-party sales. The capital expenditure for this initiative stands at ₹750 crore.

Financial Performance

The company reported a standalone net profit of ₹12 crore for Q1FY27, reversing a net loss of ₹3 crore in Q1FY26. Revenue from operations rose 15% to ₹304 crore from ₹263 crore in the corresponding period last year.

What the Numbers Show

The simultaneous rise in revenue and the transition from a net loss to a net profit suggests effective cost structure management. The revenue increase of 15% coupled with a 150% surge in EBITDA underscores financial recovery. Notably, the EBITDA margin expanded from 3% to 8%, indicating improving operating leverage as the merged entity optimizes its integrated cephalosporin platform.

Operational and Strategic Updates

Management highlighted that FY26 was challenging for the cephalosporin business, with combined revenue falling to ₹1,233 crore from ₹1,398 crore in FY25 due to volume and pricing pressures. Gross margins moderated by approximately 4 percentage points to 32% in FY26 compared to 36% in FY25. However, combined employee and other operating expenses remained broadly flat at ₹353 crore in both years.

In Q1FY27, gross margins improved by approximately 3 percentage points to 33%. The Antimicrobial Stewardship (AMS) business continues to be managed with financial discipline, with quarterly EBITDA drag reducing significantly. AMS revenue was approximately ₹5 crore in the quarter, with an EBITDA loss of around ₹50 lakh.

Pipeline and Project Timelines

Orchid Pharma provided updates on key strategic projects:

• Exblifep: In Europe, volumes grew by approximately 300% in Q3FY26, 170% in Q4FY26, and 50% in Q1FY27. Registration in South Africa is complete, with coverage across GCC markets. Discussions are advanced for South America, Mexico, Philippines, Thailand, Morocco, and Australia. The estimated 10-year value of the licensing arrangement in Russia is approximately $178 million.
• Cefiderocol: The project remains on schedule for commissioning by December 2026. Validation and initial batches are targeted for January to March 2027. Commercial launch depends on DCGI approval, potentially via a trial waiver precedent set by Cefepime-Enmetazobactam. GARDP has floated a global RFP for market access in 135 countries.
• 7-ACA Project: Commissioning and the first commercial batch are targeted by March 2027. This backward integration project aims to reach 80-100% utilization by the end of the first year, with 80% intended for in-house use and 20% for third-party sales. The capex for this project is ₹750 crore.